Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Perspective Therapeutics, retaining the price target of $5.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alec Stranahan has given his Hold rating due to a combination of factors surrounding Perspective Therapeutics’s current position in the market. The company’s recent data presentation at ESMO showed a 44% objective response rate (ORR) for their VMT-α-NET treatment, which is a decline from previous results and falls short of competitor Sanofi’s AlphaMedix, which reported a 60% ORR. This suggests that Perspective is lagging behind in terms of efficacy, which is a crucial metric for treatment selection according to key opinion leaders.
Additionally, while VMT-α-NET may offer a more favorable safety profile with fewer severe adverse events compared to AlphaMedix, the potential trade-off between safety and efficacy remains uncertain. The ongoing development and future data releases, particularly those expected in 2026, will be critical in determining whether Perspective can improve its competitive stance. Until more conclusive data is available, the Hold rating reflects a cautious approach, acknowledging both the potential and the current limitations of Perspective’s offerings.